TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06727604: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Sponsor: Immunovant Sciences GmbH · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 240 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06727604 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06727604 Rescue Dossier →